Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 20:32:100552.
doi: 10.1016/j.gore.2020.100552. eCollection 2020 May.

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma

Megan Lander  1   2 , Yasmin Abedin  1   2 , Sofia Gabrilovich  1   2 , Jenna Z Marcus  1   2
Affiliations
Case Reports

Severe hypertriglyceridemia during treatment with intraperitoneal cisplatin and paclitaxel for advanced stage fallopian tube carcinoma

Megan Lander et al. Gynecol Oncol Rep. .

Abstract

This case report describes a patient who developed severe hypertriglyceridemia (1871 mg/dL) and hyperlipidemia (LDL 132 mg/dL) during intraperitoneal (IP) administration of cisplatin and paclitaxel as adjuvant treatment for stage IIIC fallopian tube carcinoma. After an evaluation with her primary care physician, she was treated with gemfibrozil and rosuvastatin for the duration of her treatment. There was complete resolution of hypertriglyceridemia after completion of chemotherapy. This adverse event is rare and has not been reported in the literature with this chemotherapeutic regimen. A pre-chemotherapy evaluation for dyslipidemia may be beneficial in the detection and monitoring of this condition.

Keywords: Cisplatin; Fallopian tube carcinoma; Hypertriglyceridemia; Intraperitoneal; Paclitaxel.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Armstrong D.K. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 2006;354(1):34–43. - PubMed
    1. Walker J.L. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol. Oncol. 2006;100(1):27–32. - PubMed
    1. Yuan G., Al-Shali K.Z., Hegele R.A. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113–1120. - PMC - PubMed
    1. Naranjo C.A. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981;30(2):239–245. - PubMed
    1. Wang G., Su C., Yin T. Paclitaxel and platinum-based chemotherapy results in transient dyslipidemia in cancer patients. Mol. Clin. Oncol. 2017;6(2):261–265. - PMC - PubMed

Publication types

LinkOut - more resources